49th Macula Society Annual Meeting

Meet our team to explore how RetinAI's AI-powered solutions can enhance your clinical trials and real-world evidence projects

Book the Meeting

25-28 Feb

Hotel del Coronado, CA

Meet with the team!

Let's discuss how AI-based imaging analysis and real-world evidence can improve candidate identification, site selection, and trial execution. Meet with Aunia Grogan, VP Business Development and Natasa Jovic, VP Marketing Strategy & Research Partnerships & Lisa Williams, Sr. Director Commercial Operations

Book the Meeting

Scientific Presentations Featuring RetinAI Discovery

Discover new applications of RetinAI Discovery® across retinal disease research and clinical trials.

25 Feb

Clinical Implications of Measuring Macular Atrophy Progression Rate

⏱️ 5:25 PM - 5:30 PM I Part of Session: NON NV AMD I: GA I
🗣 Itay Chowers, MD
; Hadassah - Hebrew University Medical Center

Multimodal Correlation of Visual Function and High-Resolution OCT (Hi-Res OCT) Findings in Geographic Atrophy (GA) Patients: Influence of Preferred Retinal Location (PRL) Distance

⏱️ 5:05 PM - 5:10 PM I Part of Session: NON NV AMD I: GA I
🗣 Karl Csaky, MD, PhD;
Retina Foundation of the Southwest

26 Feb

Retinal Fluid Dynamics with the Sustained-release, Bioerodible Insert EYP-1901 (vorolanib intravitreal insert): Higher-order OCT Analytics Using AI Segmentation of Images from the DAVIO 2 Trial

⏱️ 1:13 PM - 1:18 PM I Part of Session: ARTIFICIAL INTELLIGENCE
🗣 Charles Clifton Wykoff, MD, PhD; Physician, Surgeon, Director of Research (RCTx), Chairman of Research & Clinical Trials (RCA), Retina Consultants of Texas (RCTx), Retina Consultants of America (RCA)